Home > Insider Trading > Filing (0001209191-21-035596)

Filing Details

Accession Number:: 0001209191-21-035596
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2021-05-24 21:25:43
Reporting Period:: 2021-05-20

Accepted Time:: 2021-05-24 21:25:43
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1706431	Vir Biotechnology Inc.	VIR	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1207792	J Robert More	C/O Vir Biotechnology, Inc. 499 Illinois Street, Suite 500 San Francisco CA 94158		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Disposition	2021-05-20	2,575	$43.57	98,430	No	4	S	Direct
Common Stock	Disposition	2021-05-20	9,095	$44.77	89,335	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	S	Direct
No	4	S	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	486,111	Indirect	See footnote

Footnotes

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 24, 2021.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $43.16 to $44.13, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
Includes 30,354 shares received in a pro-rata distribution from Alta Partners NextGen Fund I, L.P. (APNG 1) which was effected on April 5, 2021.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $44.22 to $45.03, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
The shares are held by APNG 1. The reporting person is a managing director of Alta Partners NextGen Fund I Management, LLC, which is the general partner of APNG 1. As such, the reporting person may be deemed to beneficially own the shares held by APNG 1. However, the reporting person disclaims beneficial ownership of such securities, except to the extent of his pecuniary interest therein, and this report shall not be deemed to be an admission that the reporting person is the beneficial owner of such securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise. On April 5, 2021, APNG 1 effected, without consideration, a pro-rata in-kind distribution of 486,110 shares to its partners. In prior reports, the reporting person reported indirect beneficial ownership of 972,221 shares of the Issuer held by APNG 1.